|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Begnami MD, Fukuda E, Fregnani JH,
Nonogaki S, Montagnini AL, da Costa WL Jr and Soares FA: Prognostic
implications of altered human epidermal growth factor receptors
(HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor
outcome. J Clin Oncol. 29:3030–3036. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kurokawa Y, Matsuura N, Kimura Y, Adachi
S, Fujita J, Imamura H, Kobayashi K, Yokoyama Y, Shaker MN,
Takiguchi S, et al: Multicenter large-scale study of prognostic
impact of HER2 expression in patients with resectable gastric
cancer. Gastric Cancer. 18:691–697. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kang JH, Lee SI, Lim Do H, Park KW, Oh SY,
Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, et al: Salvage
chemotherapy for pretreated gastric cancer: A randomized phase III
trial comparing chemotherapy plus best supportive care with best
supportive care alone. J Clin Oncol. 30:1513–1538. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thuss-Patience PC, Kretzschmar A, Bichev
D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G
and Reichardt P: Survival advantage for irinotecan versus best
supportive care as second-line chemotherapy in gastric cancer-a
randomised phase III study of the Arbeitsgemeinschaft
Internistische Onkologie (AIO). Eur J Cancer. 47:2306–2314. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hironaka S, Ueda S, Yasui H, Nishina T,
Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki
T, et al: Randomized, open-label, phase III study comparing
irinotecan with paclitaxel in patients with advanced gastric cancer
without severe peritoneal metastasis after failure of prior
combination chemotherapy using fluoropyrimidine plus platinum: WJOG
4007 trial. J Clin Oncol. 31:4438–4444. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry
DR, et al: Ramucirumab monotherapy for previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An
international, randomised, multicentre, placebo-controlled, phase 3
trial. Lancet. 383:31–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chrom P, Stec R and Szczylik C:
Second-line treatment of advanced gastric cancer: Current options
and future perspectives. Anticancer Res. 35:4575–4583.
2015.PubMed/NCBI
|
|
11
|
Hofmann M, Stoss O, Shi D, Büttner R, van
de Vijver M, Kim W, Ochiai A, Rüschoff J and Henkel T: Assessment
of a HER2 scoring system for gastric cancer: results from a
validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lauren P: The two histological main types
of gastric carcinoma: Diffuse and so-called intestinal-type
carcinoma. An attempt at a histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965.PubMed/NCBI
|
|
13
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gomez-Martín C, Lopez-Rios F, Aparicio J,
Barriuso J, García-Carbonero R, Pazo R, Rivera F, Salgado M, Salud
A, Vázquez-Sequeiros E and Lordick F: A critical review of
HER2-positive gastric cancer evaluation and treatment: From
trastuzumab, and beyond. Cancer Lett. 351:30–40. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Boku N: HER2-positive gastric cancer.
Gastric Cancer. 17:1–12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ryu MH, Yoo C, Kim JG, Ryoo BY, Park YS,
Park SR, Han HS, Chung IJ, Song EK, Lee KH, et al: Multicenter
phase II study of trastuzumab in combination with capecitabine and
oxaliplatin for advanced gastric cancer. Eur J Cancer. 51:482–488.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mitsui Y, Sato Y, Miyamoto H, Fujino Y,
Takaoka T, Miyoshi J, Kagawa M, Ohnuma H, Hirakawa M, Kubo T, et
al: Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS)
for patients with HER2-positive metastatic gastric cancer:
Feasibility and preliminary efficacy. Cancer Chemother Pharmacol.
76:375–382. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kang YK, Rha SY, Tassone P, Barriuso J, Yu
R, Szado T, Garg A and Bang YJ: A phase IIa dose-finding and safety
study of first-line pertuzumab in combination with trastuzumab,
capecitabine and cisplatin in patients with HER2-positive advanced
gastric cancer. Br J Cancer. 111:660–666. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kurokawa Y, Sugimoto N, Miwa H, Tsuda M,
Nishina S, Okuda H, Imamura H, Gamoh M, Sakai D, Shimokawa T, et
al: Phase II study of trastuzumab in combination with S-1 plus
cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer.
110:1163–1168. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chua C, Tan IB, Yamada Y, Rha SY, Yong WP,
Ong WS, Tham CK, Ng M, Tai DW, Iwasa S, et al: Phase II study of
trastuzumab in combination with S-1 and cisplatin in the first-line
treatment of human epidermal growth factor receptor HER2-positive
advanced gastric cancer. Cancer Chemother Pharmacol. 76:397–408.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Honma Y, Shimada Y, Takashima A, Iwasa S,
Kato K, Hamaguchi T, Yamada Y, Taniguchi H, Sekine S and Kushima R:
Efficacy of S-1 plus cisplatin combination chemotherapy in patients
with HER2-positive advanced gastric cancer. Int J Clin Oncol.
19:863–870. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM,
Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, et
al: HER2 screening data from ToGA: Targeting HER2 in gastric and
gastroesophageal junction cancer. Gastric Cancer. 18:476–484. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ock CY, Lee KW, Kim JW, Kim JS, Kim TY,
Lee KH, Han SW, Im SA, Kim TY, Kim WH, et al: Optimal patient
selection for trastuzumab treatment in HER2-positive advanced
gastric cancer. Clin Cancer Res. 21:2520–2529. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nashimoto A, Akazawa K, Isobe Y, Miyashiro
I, Katai H, Kodera Y, Tsujitani S, Seto Y, Furukawa H, Oda I, et
al: Gastric cancer treated in 2002 in Japan: 2009 annual report of
the JGCA nationwide registry. Gastric Cancer. 16:1–27. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qiu MZ, Li Q, Wang ZQ, Liu TS, Liu Q, Wei
XL, Jin Y, Wang DS, Ren C, Bai L, et al: HER2-positive patients
receiving trastuzumab treatment have a comparable prognosis with
HER2-negative advanced gastric cancer patients: A prospective
cohort observation. Int J Cancer. 134:2468–2477. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shitara K, Yatabe Y, Matsuo K, Sugano M,
Kondo C, Takahari D, Ura T, Tajika M, Ito S and Muro K: Prognosis
of patients with advanced gastric cancer by HER2 status and
trastuzumab treatment. Gastric Cancer. 16:261–267. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Namikawa T, Shiga M, Ichikawa K, Kitagawa
H, Kobayashi M and Hanazaki K: Metachronous liver and bone
metastasis from small early gastric carcinoma without lymph node
involvement: A case report. Mol Clin Oncol. 1:249–252.
2013.PubMed/NCBI
|
